From this study based on HER2 CISH and FISH data from 365 different primary breast cancer specimens it is confirmed that the FDA approved HER2 CISH pharmDxTM Kit is a reliable chromogenic alternative to today's FDA approved FISH techniques for HER2 gene status determination in FFPE breast carcinoma specimens. The gene discussed is ERBB2; the disease is breast carcinoma.